Source: FDA, National Drug Code (US) Revision Year: 2017
PLETAL (cilostazol) is a quinolinone derivative that inhibits cellular phosphodiesterase (more specific for phosphodiesterase III). The empirical formula of cilostazol is C20H27N5O2, and its molecular weight is 369.46. Cilostazol is 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, CAS-73963-72-1.
The structural formula is:
Cilostazol occurs as white to off-white crystals or as a crystalline powder that is slightly soluble in methanol and ethanol, and is practically insoluble in water, 0.1 N HCl, and 0.1 N NaOH.
PLETAL (cilostazol) tablets for oral administration are available in 50 mg triangular and 100 mg round, white debossed tablets. Each tablet, in addition to the active ingredient, contains the following inactive ingredients: carboxymethylcellulose calcium, corn starch, hydroxypropyl methylcellulose 2910, magnesium stearate, and microcrystalline cellulose.
| Dosage Forms and Strengths |
|---|
|
PLETAL is available as 50 mg triangular and 100 mg round, white debossed tablets. |
| How Supplied |
|---|
|
PLETAL is supplied as 50 mg and 100 mg tablets. The 50 mg tablets are white, triangular, debossed with PLETAL 50, and provided in bottles of 60 tablets (NDC 59148-003-16). The 100 mg tablets are white, round, debossed with PLETAL 100, and provided in bottles of 60 tablets (NDC 59148-002-16). Manufactured for: OTSUKA AMERICA PHARMACEUTICAL, INC., Rockville, MD 20850 Manufactured by: OTSUKA PHARMACEUTICAL CO., LTD., Tokushima 771-0182, Japan |
| Drug | Countries | |
|---|---|---|
| PLETAL | Germany, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
